Carcinogenesis, Vol. 22, No. 3, 515-517,
March 2001
© 2001 Oxford University Press
SHORT COMMUNICATION |
Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants
1 Division of Cancer-Related Genes, Institute for Genetic Medicine, Hokkaido University, N-15 W-7, Kita-Ku, Sapporo, 060-0815, Japan,
2 Third Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-Ku, Kyoto 602-8566, Japan and
3 Oncogene Group, Swiss Institute for Experimental Cancer Research (ISREC), Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland
Several reports have noted epidemiological differences in the prevalence or prognostic significance of p53 mutants with arginine (R) or proline (P) at the codon 72 polymorphism (R72/P72) in certain cancer types, but the biological significance of these variants is unclear. The ability of p53 mutants to interact with and inactivate the p53 homolog p73 was recently reported to depend on the conformational state of the p53 protein and the residue at codon 72. Since the conformation of p53 mutants may influence their ability to transdominantly inhibit wild-type p53, we tested whether there was a correlation between the amino acid at codon 72 and the transdominance of p53 alleles found in tumors. The transdominance test was performed using a simple yeast transcription assay, and the amino acid at codon 72 was determined by sequencing. A total of 100 p53 mutants were tested. Compared with the germline frequency (R:P = 427:297), an extreme bias in favor of the R72 allele was observed with recessive mutants (R:P = 50:7, P < 0.0002), whereas no selection for the R72 allele was seen with transdominant mutants (R:P = 23:20). p53 and p73 are known to transactivate overlapping sets of target genes. We interpret the R72 bias with recessive mutants as evidence that decreased activation of p53 target genes provides a selective growth advantage to tumor cells during the stage of tumorigenesis in which a wild-type and mutant p53 allele coexist. We suggest that transdominant p53 mutants achieve this by inactivation of the remaining wild-type p53 allele, whereas recessive p53 mutants achieve it through inactivation of p73.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Lind, P. O. Ekstrom, D. Ryberg, V. Skaug, T. Andreassen, L. Stangeland, A. Haugen, and S. Zienolddiny Frequency of TP53 Mutations in Relation to Arg72Pro Genotypes in Non Small Cell Lung Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 2077 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Mitra, S Banerjee, C Misra, R K Singh, A Roy, A Sengupta, C K Panda, and S Roychoudhury Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian patient population J. Clin. Pathol., September 1, 2007; 60(9): 1040 - 1047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Jain, V. Singh, S. Hedau, S. Kumar, M. K. Daga, R. Dewan, N. S. Murthy, S. A. Husain, and B. C. Das Infection of Human Papillomavirus Type 18 and p53 Codon 72 Polymorphism in Lung Cancer Patients From India Chest, December 1, 2005; 128(6): 3999 - 4007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Nelson, M. Wilkojmen, C. J. Marsit, and K. T. Kelsey TP53 mutation, allelism and survival in non-small cell lung cancer Carcinogenesis, October 1, 2005; 26(10): 1770 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Hu, M. P. McDermott, and S. A. Ahrendt The p53 Codon 72 Proline Allele Is Associated with p53 Gene Mutations in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2005; 11(7): 2502 - 2509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Mechanic, A. J. Marrogi, J. A. Welsh, E. D. Bowman, M. A. Khan, L. Enewold, Y.-L. Zheng, S. Chanock, P. G. Shields, and C. C. Harris Polymorphisms in XPD and TP53 and mutation in human lung cancer Carcinogenesis, March 1, 2005; 26(3): 597 - 604. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Scheckenbach, O. Lieven, K. Gotte, U. Bockmuhl, R. Zotz, H. Bier, and V. Balz p53 Codon 72 Polymorphic Variants, Loss of Allele-Specific Transcription, and Human Papilloma Virus 16 and/or 18 E6 Messenger RNA Expression in Squamous Cell Carcinomas of the Head and Neck Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1805 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Langerod, I. R. K. Bukholm, A. Bregard, P. E. Lonning, T. I. Andersen, T. O. Rognum, G. I. Meling, R. A. Lothe, and A.-L. Borresen-Dale The TP53 Codon 72 Polymorphism May Affect the Function of TP53 Mutations in Breast Carcinomas but not in Colorectal Carcinomas Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1684 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Furihata, T. Takeuchi, M. Matsumoto, A. Kurabayashi, Y. Ohtsuki, N. Terao, M. Kuwahara, and T. Shuin p53 Mutation Arising in Arg72 Allele in the Tumorigenesis and Development of Carcinoma of the Urinary Tract Clin. Cancer Res., May 1, 2002; 8(5): 1192 - 1195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Tonisson, J. Zernant, A. Kurg, H. Pavel, G. Slavin, H. Roomere, A. Meiel, P. Hainaut, and A. Metspalu Evaluating the arrayed primer extension resequencing assay of TP53 tumor suppressor gene PNAS, April 16, 2002; 99(8): 5503 - 5508. [Abstract] [Full Text] [PDF]
|
|